PMID- 23179201
OWN - NLM
STAT- MEDLINE
DCOM- 20140424
LR  - 20211021
IS  - 1436-6215 (Electronic)
IS  - 1436-6207 (Linking)
VI  - 52
IP  - 6
DP  - 2013 Sep
TI  - Postprandial glucose, insulin and gastrointestinal hormones in healthy and 
      diabetic subjects fed a fructose-free and resistant starch type IV-enriched 
      enteral formula.
PG  - 1569-78
LID - 10.1007/s00394-012-0462-x [doi]
AB  - BACKGROUND: Reducing the dietary glycaemic response has been proposed as a means 
      of reducing the risk of diabetes. AIM: To evaluate the effects of a new 
      diabetes-specific formula (DSF) enriched with resistant starch type IV and 
      fructose-free on postprandial glycaemia, insulinaemia and gastrointestinal 
      hormones in healthy volunteers and in outpatient type 2 diabetics. METHODS: (1) 
      Twenty-four healthy volunteers were divided into two groups: Group 1 ( n = 10) 
      was provided 50 g of the carbohydrate (CHO) constituent of the new product and 50 
      g of glucose separated by 1 week; Group 2 ( n = 14) was provided 400 ml of the 
      new DSF (T-Diet Plus((R)) Diabet NP) and 400 ml of a control product separated by 1 
      week. (2) Ten type 2 diabetic patients received 400 ml of the new DSF and two 
      other commercially available DSF (Glucerna((R)) SR and Novasource((R)) Diabet) on 
      three occasions separated by 1 week. Venous blood samples were drawn at time 0 
      and at different times until 120 min. Glucose, insulin and gastrointestinal 
      hormones were determined. Glycaemic and insulinaemic indices and glycaemic load 
      were calculated. RESULTS: The CHO constituent and the new DSF showed low 
      glycaemic index and glycaemic load. In healthy subjects, insulin and C-peptide 
      release were lower after administration of the CHO constituent as well as after 
      the new DSF (P < 0.001). Ghrelin, glucagon-like peptide-1 (GLP-1) and 
      glucose-dependent insulinotropic peptide (GIP) production were lower after intake 
      of the CHO constituent (P ranging from <0.001 to 0.019) compared with glucose, 
      and GIP was lower after ingestion of the new DSF (P = 0.002) than after the 
      control product. In type 2 diabetic patients, glucose AUC was lower after the 
      administration of the new DSF (P = 0.037) compared with the others. CONCLUSIONS: 
      Our results indicate that this new product could be beneficial for diabetic 
      patients.
FAU - Garcia-Rodriguez, Cruz Erika
AU  - Garcia-Rodriguez CE
AD  - Department of Biochemistry and Molecular Biology II, Institute of Nutrition and 
      Food Technology "Jose Mataix", Biomedical Research Centre, University of Granada, 
      Avenida del Conocimiento s/n, 18100 Armilla, Granada, Spain. erikagr@ugr.es
FAU - Mesa, Maria Dolores
AU  - Mesa MD
FAU - Olza, Josune
AU  - Olza J
FAU - Buccianti, Gilda
AU  - Buccianti G
FAU - Perez, Milagros
AU  - Perez M
FAU - Moreno-Torres, Rosario
AU  - Moreno-Torres R
FAU - Perez de la Cruz, Antonio
AU  - Perez de la Cruz A
FAU - Gil, Angel
AU  - Gil A
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20121123
PL  - Germany
TA  - Eur J Nutr
JT  - European journal of nutrition
JID - 100888704
RN  - 0 (Blood Glucose)
RN  - 0 (C-Peptide)
RN  - 0 (Dietary Carbohydrates)
RN  - 0 (Dietary Fats, Unsaturated)
RN  - 0 (Fatty Acids, Omega-3)
RN  - 0 (Ghrelin)
RN  - 0 (Glucerna)
RN  - 0 (Insulin)
RN  - 0 (Lipids)
RN  - 30237-26-4 (Fructose)
RN  - 59392-49-3 (Gastric Inhibitory Polypeptide)
RN  - 89750-14-1 (Glucagon-Like Peptide 1)
RN  - 9005-25-8 (Starch)
SB  - IM
MH  - Adult
MH  - Area Under Curve
MH  - Blood Glucose/metabolism
MH  - C-Peptide/metabolism
MH  - Diabetes Mellitus, Type 2/blood/*diet therapy
MH  - Dietary Carbohydrates/administration & dosage
MH  - Dietary Fats, Unsaturated/administration & dosage
MH  - *Dietary Supplements
MH  - *Enteral Nutrition
MH  - Fatty Acids, Omega-3/administration & dosage
MH  - Female
MH  - Fructose/*administration & dosage
MH  - Gastric Inhibitory Polypeptide/blood
MH  - Ghrelin/blood
MH  - Glucagon-Like Peptide 1/blood
MH  - Glycemic Index
MH  - Healthy Volunteers
MH  - Humans
MH  - Insulin/blood
MH  - Lipids/blood
MH  - Male
MH  - Middle Aged
MH  - *Postprandial Period
MH  - Starch/*administration & dosage
MH  - Young Adult
EDAT- 2012/11/28 06:00
MHDA- 2014/04/25 06:00
CRDT- 2012/11/27 06:00
PHST- 2012/07/25 00:00 [received]
PHST- 2012/11/05 00:00 [accepted]
PHST- 2012/11/27 06:00 [entrez]
PHST- 2012/11/28 06:00 [pubmed]
PHST- 2014/04/25 06:00 [medline]
AID - 10.1007/s00394-012-0462-x [doi]
PST - ppublish
SO  - Eur J Nutr. 2013 Sep;52(6):1569-78. doi: 10.1007/s00394-012-0462-x. Epub 2012 Nov 
      23.